

NEKTAR THERAPEUTICS  
Form 8-K  
June 23, 2003

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## FORM 8-K

**Current Report Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 23, 2003**

### **Nektar Therapeutics**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**000-23556**

(Commission File No.)

**94-3134940**

(IRS Employer Identification No.)

**150 Industrial Road  
San Carlos, CA 94070**

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(650) 631-3100**

**Item 5. Other Events**

On June 23, 2003, Nektar Therapeutics announced its intention to issue \$100 million aggregate principal amount of convertible subordinated notes (\$125 million if an over-allotment option is exercised in full).

Nektar's press release, dated June 23, 2003, titled "Nektar Therapeutics Announces Proposed Issuance of Convertible Subordinated Notes" is attached hereto as Exhibit 99.1.

**Item 7. Financial Statements and Exhibits**

**(c) Exhibits**

Exhibit Number	Description
99.1	Press Release titled "Nektar Therapeutics Announces Proposed Issuance of Convertible Subordinated Notes" dated June 23, 2003.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**NEKTAR THERAPEUTICS**

Dated: June 23, 2003

By: /s/ Ajay Bansal

Ajay Bansal

*Chief Financial Officer and Vice President, Finance  
and Administration*